Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization
Open Access
- 20 August 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 1030
Abstract
Background: Prophylaxis in children with hemophilia B (HB) lacks quantitative approaches that integrate both plasma exposure and tissue distribution. This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model of factor IX (FIX) for pediatric HB. The model incorporated the binding of FIX to type IV collagen (Col4) to characterize its distribution in both plasma and extravascular tissues. Methods: A total of 20 children with severe HB were included, contributing 219 plasma samples. The base PBPK model was first established and verified using adult and plasma-derived FIX (pdFIX) data. It was subsequently extrapolated to children by integrating FIX-CTBB parameters and pediatric observations for model calibration. The validated model was used to characterize plasma pharmacokinetics, predict tissue distribution and target attainment, and simulate alternative prophylactic dosing regimens. Results: The model adequately described the plasma pharmacokinetics of FIX in children and predicted substantial extravascular distribution. Total extravascular exposure was approximately sixfold higher than plasma exposure. Marked heterogeneity in target attainment was identified across tissues. Lower target attainment was observed in the colon, pancreas, and brain, whereas delayed attainment occurred in bone and muscle. Simulations of prophylactic dosing regimens suggested that 75 IU/kg twice weekly may provide a favorable balance among sustained FIX exposure, tissue-level target attainment, and treatment burden. Conclusions: This PBPK model provides a mechanistic and quantitative framework for characterizing plasma and tissue exposure to FIX in children with HB and may support individualized optimization of FIX prophylactic dosing.Keywords
Funding Information
- Peking University Third Hospital (BYSYZD2021002)
- Beijing Municipal Administration of Hospitals (PX2024043)
This publication has 53 references indexed in Scilit:
- Global sensitivity analysis of Open Systems Pharmacology Suite physiologically based pharmacokinetic modelsCPT: Pharmacometrics & Systems Pharmacology, 2024
- Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare DiseasesClinical Pharmacology & Therapeutics, 2024
- PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular spaceCPT: Pharmacometrics & Systems Pharmacology, 2024
- ISTH clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology: considerations for practice management and implementationJournal of Thrombosis and Haemostasis, 2024
- Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European CountriesAdvances in Therapy, 2023
- Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal speciesCPT: Pharmacometrics & Systems Pharmacology, 2023
- A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-SimJournal of Pharmacokinetics and Pharmacodynamics, 2017
- The growing number of hemophilia registries: Quantity vs. qualityClinical Pharmacology & Therapeutics, 2015
- Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxisEuropean Journal of Clinical Pharmacology, 2012
- Pharmacokinetics of factor IX in patients with haemophilia BEuropean Journal of Clinical Pharmacology, 1994